Apellis Pharmaceuticals Stock Current Liabilities
| APLS Stock | USD 23.15 0.99 4.10% |
Fundamental analysis of Apellis Pharmaceuticals allows traders to better anticipate movements in Apellis Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Apellis Pharmaceuticals Company Current Liabilities Analysis
Apellis Pharmaceuticals' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Apellis Pharmaceuticals Current Liabilities | 5.13 M |
Most of Apellis Pharmaceuticals' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Apellis Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Apellis Pharmaceuticals has a Current Liabilities of 5.13 M. This is 99.71% lower than that of the Biotechnology sector and 99.05% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.94% higher than that of the company.
Apellis Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Apellis Pharmaceuticals' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Apellis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Apellis Pharmaceuticals by comparing valuation metrics of similar companies.Apellis Pharmaceuticals is currently under evaluation in current liabilities category among its peers.
Apellis Fundamentals
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 3.02 B | ||||
| Shares Outstanding | 126.29 M | ||||
| Shares Owned By Insiders | 13.68 % | ||||
| Shares Owned By Institutions | 86.32 % | ||||
| Number Of Shares Shorted | 21.05 M | ||||
| Price To Earning | (6.94) X | ||||
| Price To Book | 18.67 X | ||||
| Price To Sales | 4.04 X | ||||
| Revenue | 781.37 M | ||||
| Gross Profit | 313.89 M | ||||
| EBITDA | (154.53 M) | ||||
| Net Income | (197.88 M) | ||||
| Cash And Equivalents | 852.8 M | ||||
| Cash Per Share | 7.76 X | ||||
| Total Debt | 469.78 M | ||||
| Debt To Equity | 0.63 % | ||||
| Current Ratio | 7.57 X | ||||
| Book Value Per Share | 1.24 X | ||||
| Cash Flow From Operations | (87.87 M) | ||||
| Short Ratio | 9.23 X | ||||
| Earnings Per Share | (1.83) X | ||||
| Price To Earnings To Growth | (0.30) X | ||||
| Target Price | 37.44 | ||||
| Number Of Employees | 705 | ||||
| Beta | 0.68 | ||||
| Market Capitalization | 3.05 B | ||||
| Total Asset | 885.05 M | ||||
| Retained Earnings | (3.04 B) | ||||
| Working Capital | 603.45 M | ||||
| Current Asset | 115.82 M | ||||
| Current Liabilities | 5.13 M | ||||
| Net Asset | 885.05 M |
About Apellis Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Apellis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apellis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apellis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.